Morgan Stanley Maintains Overweight on Ryan Specialty (RYAN), Citing Sector Strength

RYAN Specialty Holdings, Inc. (NYSE:RYAN) is one of the high growth stocks outside tech analysts are bullish on. On July 14, Morgan Stanley analyst Bob Huang increased the price target on RYAN Specialty Holdings, Inc. (NYSE:RYAN) to $80, up from $78, while maintaining an Overweight rating. Based on the current market price of $60.80, the revised target suggests a potential upside of approximately 31.6%.

A portrait of a professional insurance broker at their desk, reviewing a policy.

This update is part of Morgan Stanley’s broader reassessment of companies within the Property & Casualty (P&C) Insurance sector. The firm noted that recent financial results across the sector varied depending on the type of business, but certain areas, particularly personal insurance lines, are showing encouraging signs of strength. Analysts believe this momentum can carry into 2025. As market conditions head toward greater stability, Morgan Stanley expects brokers and personal line insurers to be the key earnings drivers within the industry. For Ryan Specialty, this could translate into steady revenue growth as demand for specialized insurance services continues.

While the report doesn’t suggest dramatic changes in the broader sector, it highlights how companies like Ryan Specialty are positioned to benefit from steady, long-term trends. The focus on profitability and operating efficiency is expected to support the stock’s performance moving forward.

Ryan Specialty is a wholesale insurance broker that provides specialty solutions for complex and hard-to-place risks.

While we acknowledge the potential of RYAN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Consumer Stocks to Buy Now and 10 Best High-Margin Pharma Stocks to Buy Now.

Disclosure: None.